stock-detail (IMUC)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

TSRI and JCVI Scientists Find Popular Stem Cell Techniques Safe

2/22/2016 11:04 am

(TSRI) Feb 19, 2016 - A new study led by scientists at The Scripps Research Institute (TSRI) and the J. Craig Venter Institute (JCVI) shows that the act of creating pluripotent stem cells for clinical use is unlikely to pass on cancer-causing mutations to patients.

ASCO Commends Dr. Harold Varmus’ Outstanding Leadership as NCI Director

3/5/2015 12:01 pm

(ASCO) Mar 5, 2015 - The American Society of Clinical Oncology (ASCO) is enormously grateful for the service and leadership of Harold Varmus, MD, as Director of the National Cancer Institute (NCI).

Brandicourt as Sanofi Chief to Focus on Taking Drugs to U.S.

2/20/2015 11:01 am

(Bloomberg) Feb 19, 2015 - Olivier Brandicourt, whose track record includes the introduction of the best-selling drug in history, takes the helm at Sanofi with the mandate of bringing new drugs to the U.S. after missteps led to his predecessor’s ouster.

Does Pharma Money Mix With Cash Receptors in Your Doctor’s Wallet?

2/9/2015 12:00 pm

(Wall Street Journal/Pharmalot blog) Feb 9, 2015 - In a mocking, but pointed segment on Last Week Tonight, comedian John Oliver recaps the controversy over marketing to doctors, which has embroiled the pharmaceutical industry in recent years.

Specialist Doctors Head for Exit as U.S. Shifts Payments

2/2/2015 06:04 am

(Bloomberg) Feb 2, 2015 - The Obama administration’s push to transform the way the U.S. pays for health care is splitting the medical profession, as family doctors embrace changes that oncologists, neurologists and other specialists are concerned will cause turmoil.

Merck Will No Longer Sell its Victrelis Hepatitis C Drug in the U.S.

1/21/2015 01:01 pm

(Wall Street Journal/Pharmalot blog) Jan 21, 2015 - Rival hepatitis C drugs from Merck and Vertex Pharmaceuticals made a big splash when they debuted in 2011, marking an advance in treatment of the liver disease and a lucrative new market segment.

Brain Tumor Community Pushes For Inclusion of Patient-Focused Endpoints in Future Clinical Trials

11/7/2014 06:02 am

(National Brian Tumor Society) Nov 6, 2014 - A recent workshop brought together leaders and stakeholders from the neuro-oncology, neurology, and clinical outcomes assessment fields to address the critical issue of incorporating patient-focused endpoints into future brain cancer clinical trials.

Roche CEO Rules Out Big Deals

9/17/2014 07:02 am

(Wall Street Journal) Sept 17, 2014 - Roche won't change its acquisition strategy following the recent spate of megadeals signed or abandoned in the pharmaceutical sector, Chief Executive Severin Schwan said in an interview.

Research Finds No Association Between Wearing a Bra and Breast Cancer

9/5/2014 06:00 am

(AACR) Sept 5, 2014 - A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Allergan's Ozurdex Gets FDA Nod

6/30/2014 06:03 am

(Wall Street Journal) June 30, 2014 - Allergan Inc. said Monday that the U.S. Food and Drug Administration had approved its Ozurdex eye treatment, while reporting positive midstage results for other drugs in its pipeline.

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting

6/1/2014 01:04 pm

(ImmunoCellular) June 1, 2014 - ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 ASCO annual meeting in Chicago.

ImmunoCellular Therapeutics Announces ICT-107 Phase II Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting

4/22/2014 11:05 am

(San Francisco Business Times) Apr 21, 2014 - ImmunoCellular Therapeutics, Ltd. today announced that the abstract describing the Company's phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma (GBM) has been accepted for an oral presentation at the 2014 ASCO annual meeting in Chicago.

ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union

2/25/2014 11:05 am

(Yahoo! Finance) Feb 25, 2014 - ImmunoCellular Therapeutics, Ltd. announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma.

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

1/3/2014 11:05 am

(The Street) Jan 3, 2014 - Happy New Year and welcome back to the Biotech Stock Mailbag. Today marks the start of the eighth year for this column, which wouldn't be possible without your questions and comments. Thank you so much.

ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

1/2/2014 11:05 am

(Immunocellular) Dec 23, 2013 - ImmunoCellular Therapeutics, Ltd. announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme (GBM, or brain cancer), has received the vaccine.

Why Northwest Bio's DCVax Brain Tumor Vaccine Will Blow Up Just Like ImmunoCellular's ICT-107

12/18/2013 11:00 am

(TheStreet) Dec 17, 2013 - Dendritic cancer vaccines are too weak to be effective.

ImmunoCellular's Lead Product Misses Key Endpoint

12/12/2013 12:05 pm

(Wall Street Journal) Dec 12, 2013 - ImmunoCellular's leading candidate, a vaccine for brain cancer, didn't show a significant advantage in overall survival in a mid-stage study.

ImmunoCellular Therapeutics Phase II Study Demonstrates That Glioblastoma Patients Live Longer Without Disease Progression When Treated With ICT-107

12/12/2013 06:03 am

(Benzinga) Dec 11, 2013 - ImmunoCellular Therapeutics, Ltd. announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.

Novel Drug Prevents Common Viral Disease in Stem-Cell Transplant Patients, Study Finds

9/27/2013 11:01 am

(Dana-Farber Cancer Institute) Sep 26, 2013 - A common, sometimes severe viral disease in patients receiving a transplant of donated stem cells can be prevented by a new drug given shortly after transplant, according to a study led by Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers.

GSK Cancer Drug Combination Wins US Priority Review

9/16/2013 06:02 am

(Reuters) Sep 16, 2013 - A combination treatment from GlaxoSmithkline for melanoma, the deadliest form of skin cancer, has won priority review from U.S. regulators.

ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

7/30/2013 11:04 am

(Yahoo! Finance) July 30, 2013 - ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM).

ImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis

6/10/2013 12:00 pm

(Daily Finance) June 7, 2013 - ImmunoCellular Therapeutics, Ltd. announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.

Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics

2/8/2013 12:02 pm

(TheStreet) Feb 8, 2013 - Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Researchers Use New Molecular Inhibitors to Successfully Hit Difficult Cancer Target

2/7/2013 12:02 pm

(Cincinnati Children's) Feb 6, 2013 - Early laboratory tests are the first to successfully use an experimental molecular therapy to block a hard-to-target part of a protein complex linked to several types of invasive cancer.

FDA Drug Safety Communication: Safety Review Update of Cancer Drug Revlimid (Lenalidomide) and Risk of Developing New Types of Malignancies

11/26/2012 12:04 pm

(FDA) Nov 23, 2012 - This update is in follow-up to the FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies.